Tela Bio, Inc. - TELA STOCK NEWS

TELA Bio (NASDAQ: TELA) has announced the U.S. commercial launch of larger sizes of OviTex® PRS Reinforced Tissue Matrix for plastic and reconstructive surgery. The expanded portfolio now includes a 25 x 30 cm oval and a 25 cm diameter circle, offering larger options than any human acellular dermal matrix product currently available.

The company reports significant growth with OviTex PRS, having sold nearly 15,000 units since its 2019 launch, achieving 31% year-over-year unit sales growth in 2024. The larger configurations aim to reduce the need for multiple smaller pieces during complex procedures, potentially improving surgical efficiency and reducing costs.

TELA Bio reported its Q4 and full year 2024 financial results, achieving $17.6 million in Q4 revenue (+4% YoY) and $69.3 million for full year 2024 (+19% YoY). The company saw significant growth in unit sales volume for OviTex® and OviTex PRS products, up 33% and 31% respectively.

The newly launched OviTex IHR Reinforced Tissue Matrix sold over 1,200 units since its mid-April 2024 debut. Q4 gross profit was $11.2 million (64% margin), down from 68% in Q4 2023. Full year 2024 net loss improved to $37.8 million from $46.7 million in 2023.

Looking ahead, TELA Bio projects 2025 revenue guidance of $85.0-88.0 million, representing 23-27% growth, with Q1 2025 expected at $17.0-18.0 million. The company ended 2024 with $52.7 million in cash and expects 2025 operating expenses to remain flat compared to 2024.

TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 20, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring management's discussion of financial results and a corporate update. Interested investors must register in advance or at least 15 minutes before the call. Access to the live webcast and replay will be available through the Events & Presentations page in TELA's investor section website.

TELA Bio (NASDAQ: TELA) has announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of restricted stock units covering 7,200 shares of common stock, awarded to thirteen newly-hired employees on February 19, 2025. These grants, made under Nasdaq Rule 5635(c)(4), serve as employment compensation and incentives for new hires. The restricted stock units will vest equally over four years, contingent on continued employment with TELA Bio through the specified vesting dates.

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units (RSUs) to seven new employees. The grants, totaling 4,000 shares of common stock, were issued on January 21, 2025, under Nasdaq Rule 5635(c)(4). These RSUs will vest in equal annual installments over four years, contingent upon continued employment with the company. The grants were made as part of the employees' compensation packages and served as inducements for their acceptance of employment with TELA Bio, a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions.

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units (RSUs) to three new employees. The grants, totaling 1,700 shares of common stock, were issued on December 11, 2024. These RSUs will vest in equal annual installments over four years, contingent on continued employment. The grants were made under Nasdaq Rule 5635(c)(4) as part of the employees' compensation packages and to incentivize their acceptance of employment with the company.

TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has announced its participation in Piper Sandler's 36th Annual Healthcare Conference. The company's management team will deliver a presentation on December 3rd, 2024, at 12:00 pm ET. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at ir.telabio.com.

TELA Bio reported Q3 2024 revenue of $19.0 million, marking a 26% growth year-over-year. The company saw increased demand for OviTex® and OviTex PRS products, with unit sales volume growing 39% and 44% respectively. TELA completed a public offering raising $46.0 million gross proceeds and implemented efficiency measures expected to reduce 2025 operating expenses by $5.0-$10.0 million. The company reiterated its 2024 revenue guidance of $74.5-$76.5 million, representing 27-31% growth, though noting potential impact from IV fluid shortages. Q3 gross profit was $12.9 million (68% margin), with operating expenses at $22.2 million and a net loss of $10.4 million.

TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units covering 5,400 shares to six newly-hired employees. The grants, dated November 1, 2024, were made under Nasdaq Rule 5635(c)(4) as part of employment compensation packages. These restricted stock units will vest equally over four years, contingent on continued employment with the company.